All Stories

  1. Clinical Features, Medical Management, and Patient Outcomes Following Sand Ingestion in 55 Dogs (2018–2024)
  2. Convergent biology, divergent drivers: a cross-species comparison of human and canine invasive urothelial carcinoma
  3. Corrigendum to “Evidence-based medical therapy for mitral regurgitation in dogs” [J Vet Cardiol (2026) 10.1016/j.jvc.2026.04.006]
  4. Correction: Phenylbutazone concentrations in synovial fluid following administration via intravenous regional limb perfusion in the forelimbs of six adult horses
  5. A One Health Approach to Parallel Drug Development
  6. New Frontiers of Drug Development Through the Use of New Approach Methodologies
  7. A Comprehensive Mathematical Model of Avidity in Cytokine Signaling
  8. Multi‐Institutional, Retrospective Evaluation of Risk Factors Predicting Complications Associated With Perineal Urethrostomy in Cats With Urethral Obstruction (2009–2019): 140 Cases
  9. Targeted proteomic analyses during combined angiotensin-converting enzyme inhibitor and mineralocorticoid receptor antagonist administration (CARDALIS®) in healthy dogs
  10. Are We Going to the Dogs? Human Disease Phenotypes in Canines
  11. Are We Going to the Dogs? Human Disease Phenotypes in Canines
  12. Gaps and paths forward in cancer pharmacology and translational research
  13. Evidence-Based Medical Therapy for Mitral Regurgitation in Dogs
  14. Establishment of a canine urothelial carcinoma‐derived organoid biobank: A platform for comparative and translational research
  15. Histologic and immunohistochemical characterization and frequency of rare subtypes of canine invasive urothelial carcinoma
  16. Innovative In Vitro-In Silico Platform for Dose–Response Modeling in Canine Bladder Cancer: A 3D Organoid- and Mathematics-Based Approach
  17. Effect of the sodium glucose transporter-2 inhibitor dapagliflozin on urine and blood biomarkers in dogs with heart disease
  18. Prognostic value of plasma cortisol concentration in dogs with congestive heart failure
  19. Evidence-Based Medical Therapy for Mitral Regurgitation in Dogs
  20. Leveraging Canine Disease Models in Pharmaceutical Sciences: A One Health Path to Parallel Drug Development
  21. Multicenter Retrospective Evaluation of the Use of Lyophilized Platelets in Dogs
  22. Transmucosal detomidine gel induces emesis in approximately half of cats presenting for dietary indiscretion
  23. Development and characterization of chicken lung organoids for in vitro modeling of avian influenza virus-host cell interaction
  24. Urothelial genotoxicity of household chemicals in healthy canine urinary bladder organoids relative to observed urinary exposures in pet dogs
  25. Evidence-Based Medical Therapy for Mitral Regurgitation in Dogs
  26. Establishment and transcriptomic characterization of canine organoids from multiple tissues
  27. Retrospective Comparison of Outcomes From Septic Peritonitis of Gastrointestinal Versus Non‐Gastrointestinal Etiology in Dogs (2009–2022): 161 Cases
  28. A microfluidic platform for culturing and high-content imaging of adult stem cell-derived organoids
  29. Bioengineered gut bacterium synthesizing levodopa alleviates motor deficits in models of Parkinson’s disease
  30. Development of a Time-based Drug Screening Platform for Improved Clinical Translation
  31. A Roadmap for the Future of Systems Biology in Cancer Research
  32. Retrospective Evaluation of Treatment and Survival of Blunt Trauma‐Associated Pneumothorax in Dogs: 89 Cases (2018–2022)
  33. Retrospective Evaluation of the Incidence and Risk Factors Associated With the Development of a Hepatopathy in Xylitol Ingestion: 95 Dogs (2018–2022)
  34. Interdisciplinary research seeks treatments and cures for diseases of animals and humans
  35. SUN-056 The National Biorepository and Resource for Pituitary Neuroendocrine Tumor Translational Research (BioPitNeT)
  36. Establishing a Canine Urothelial Organoid Repository: A Platform for Comparative and Translational Carcinoma Studies
  37. A comprehensive pharmacodynamic dataset reconciles 50 years of laboratory and clinical knowledge
  38. Innovative In Vitro-In Silico Platform for Dose-Response Modeling in Canine Bladder Cancer: A 3D Organoid- and Mathematics-Based Approach
  39. Letter Regarding “Recommendations for a Complete Reporting of Statistical Methods in Veterinary Pharmacology”
  40. Optimizing First‐Line Therapeutics in Non‐Small Cell Lung Cancer: Insights From Joint Modeling and Large‐Scale Data Analysis
  41. Experimental Methods for Establishing and Maintaining Canine Bladder Cancer Organoids
  42. Cancer Detection and Diagnosis
  43. Evolving value and validity of animal models in veterinary therapeutic research: Impact of scientific progress
  44. Restorative Effects of Synbiotics on Colonic Ultrastructure and Oxidative Stress in Dogs with Chronic Enteropathy
  45. OrganoidChip+: a Microfluidic Platform for Culturing, Staining, Immobilization, and High-Content Imaging of Adult Stem Cell-Derived Organoids
  46. Penicillin and Gentamicin Concentrations in the Uterine Fluid of Non‐Pregnant Mares Following a Single Intrauterine Infusion
  47. Frequency and Characterization of Rare Histologic Subtypes in Canine Invasive Urothelial Carcinoma
  48. Incidence of hypernatremia in dogs treated with multi-dose activated charcoal for acute toxicant ingestion: multi-center retrospective study (2018–2023)
  49. Pharmacokinetic evaluation and bioavailability of KPT-335 (Verdinexor) in cats
  50. Su1305: DUODENAL DNA METHYLATION PROFILES IN DOGS WITH CHRONIC INFLAMMATORY ENTEROPATHY TREATED WITH NOVEL SYNBIOTIC
  51. <span style="mso-bidi-font-weight: bold;">Spontaneous Canine Disease Models in Biomedical Science: A One Health Path to Predictive Drug Development
  52. Development and Characterization of Chicken Lung Organoids for Future In Vitro Modeling of Avian Influenza Virus-Host Cell Interaction
  53. A Preclinical Model to Assess Intestinal Barrier Integrity Using Canine Enteroids and Colonoids
  54. The association between non-depolarizing neuromuscular blockade agents and survival to discharge in dogs undergoing mechanical ventilation: a multi-center retrospective study of 227 dogs (2010–2020)
  55. Retrospective Evaluation of Complications Associated With Surgically Placed Gastrostomy Tubes in Dogs (2010–2020): 133 Cases
  56. Effects of a Western Diet on Colonic Dysbiosis, Bile Acid Dysmetabolism and Intestinal Inflammation in Clinically Healthy Dogs
  57. Incidence of hypernatremia in dogs treated with single dose activated charcoal for acute toxicant ingestion: multi-center retrospective study (2018–2023)
  58. A Novel Preclinical Model to Assess Intestinal Barrier Integrity Using Canine Enteroids and Colonoids
  59. A preliminary investigation in dogs to evaluate for post-anesthetic lung ultrasound findings suggestive of atelectasis
  60. A multi-stage feature selection method to improve classification of potential super-agers and cognitive decliners using structural brain MRI data—a UK biobank study
  61. Utilization of peripheral glucose and lactate differences in the diagnosis of feline arterial thromboembolism: a multi-center study
  62. Dose‐exposure‐response of CARDALIS® (benazepril/spironolactone) on the classical and alternative arms of the renin‐angiotensin‐aldosterone system in healthy dogs
  63. Frequency and progression of azotemia during acute and chronic treatment of congestive heart failure in cats
  64. Treatment of Canine Myxomatous Mitral Valve Disease:Current and Future Approaches
  65. University of Georgia College of Veterinary Medicine’s Precision One Health Initiative improves animal and human health by developing alternative models of disease
  66. Cisplatin-Induced Metabolic Responses Measured with Raman Spectroscopy in Cancer Cells, Spheroids, and Canine-Derived Organoids
  67. Preclinical modeling of metabolic syndrome to study the pleiotropic effects of novel antidiabetic therapy independent of obesity
  68. 166 Development of non-model organoids in animal research: A paradigm shift in in vitro models
  69. Pharmacokinetics of isavuconazonium sulfate and its active metabolite isavuconazole in healthy dogs
  70. Evaluating the Bias of Two Point-of-Care Glucometers for Calves and Ewes: Awareness for Ruminant Practitioners
  71. Systemic absorption and gastrointestinal adverse effects from topical ketorolac and diclofenac ophthalmic solutions in healthy dogs
  72. Renin-Angiotensin Aldosterone System Modulation and Cardiovascular-Kidney-Metabolic Health
  73. Population Pharmacokinetics and Absolute Oral Bioavailability of Lasalocid after Single Intravenous and Intracrop Administration in Laying Hens
  74. Abstract PR002: Sarcomatoid Histological Variants of Canine Muscle-Invasive Bladder Cancer: Transcription Factor Activation Highlights Pathways of Epithelial-Mesenchymal Transformation Similar to Humans
  75. Retrospective evaluation of the prevalence and risk factors associated with red blood cell transfusions in cats with urethral obstruction (2009–2019): 575 cases
  76. Tu1739 MICRORNAS AS POTENTIAL BIOMARKERS FOR DIAGNOSIS AND MONITORING CHRONIC INFLAMMATORY ENTEROPATHY IN DOGS
  77. Randomized comparison between a forced air system and warm water bath for resuscitation of neonatal hypothermic calves with or without oral administration of caffeine
  78. Preclinical Modeling of Metabolic Syndrome to Study the Pleiotropic Effects of Novel Antidiabetic Therapy Independent of Obesity
  79. Experimental Methods for Establishing and Maintaining Canine Bladder Cancer Organoids
  80. A machine learning approach for potential Super‐Agers identification using neuronal functional connectivity networks
  81. Evaluation of different media compositions promoting hepatocyte differentiation in the canine liver organoid model
  82. Letter regarding “Fuzapladib in a randomized controlled multicenter masked study in dogs with presumptive acute onset pancreatitis”
  83. Comparison of Traditional Didactic Versus Additional Hands-On Simulation Training in the Performance of Basic Life Support in Veterinary Students—A Prospective, Blinded, Randomized Study
  84. Comprehensive characterization of the effect of mineralocorticoid receptor antagonism with spironolactone on the renin-angiotensin-aldosterone system in healthy dogs
  85. Establishment and characterization of turtle liver organoids provides a potential model to decode their unique adaptations
  86. Effect of amlodipine on the circulating renin‐angiotensin‐aldosterone system in healthy cats
  87. Genetic Factors of Alzheimer’s Disease Modulate How Diet is Associated with Long-Term Cognitive Trajectories: A UK Biobank Study
  88. Adult Animal Stem Cell-Derived Organoids in Biomedical Research and the One Health Paradigm
  89. Leveraging the predictive power of 3D organoids in dogs to develop new treatments for man and man’s best friend
  90. A Preclinical Model of Obesity-Independent Metabolic Syndrome for Studying the Effects of Novel Antidiabetic Therapy Beyond Glycemic Control
  91. Retrospective evaluation of admission total plasma protein as a predictor of red blood cell transfusion requirement in dogs diagnosed with traumatic and nontraumatic hemoabdomen: 90 dogs (2009–2019)
  92. Exploring the benefits of in-diet versus repeated oral dosing of saracatinib (AZD0530) in chronic studies: insights into pharmacokinetics and animal welfare
  93. A Preclinical Model of Obesity-Independent Metabolic Syndrome for Studying the Effects of Novel Antidiabetic Therapy Beyond Glycemic Control
  94. Exploring the Potential Links Between Gut Bacteria-Related Metabolites and the Risk of Cardiovascular Diseases
  95. Role of the tumour microenvironment in bladder cancer pathogenesis and value of the reverse translational approach: a tale of two species
  96. Effect of the Probiotic Bacillus subtilis DE-CA9TM on Fecal Scores, Serum Oxidative Stress Markers and Fecal and Serum Metabolome in Healthy Dogs
  97. Retrospective comparison of outcomes in septic peritonitis with or without closed-suction abdominal drainage in 115 dogs (2009–2019)
  98. Phenylbutazone concentrations in synovial fluid following administration via intravenous regional limb perfusion in the forelimbs of six adult horses
  99. Gene Editing and Gene Therapy in Oncology
  100. Echocardiographic caudal vena cava measurements in healthy cats and in cats with congestive heart failure and non-cardiac causes of cavitary effusions
  101. Blood product usage and factors associated with transfusions in cats with hemoperitoneum: 33 cases (2018–2022)
  102. OrganoidChip facilitates hydrogel-free immobilization for fast and blur-free imaging of organoids
  103. Changes of Enterocyte Morphology and Enterocyte: Goblet Cell Ratios in Dogs with Protein-Losing and Non-Protein-Losing Chronic Enteropathies
  104. Increased drug concentration and repeated eye drop administration as strategies to optimize topical drug delivery: A fluorophotometric study in healthy dogs
  105. O62 | Population pharmacokinetics of sodium salicylate in chickens and turkeys – New insights into the drug's non‐linear elimination
  106. O89 | A novel biologically relevant canine in vitro model for the study of intestinal inflammation
  107. O59 | Breakthrough: A first‐in‐class virtual simulator for dose optimization of ACE inhibitors in veterinary cardiology
  108. O60 | Comparison of intestinal barrier integrity in conventional 2D cell lines and canine duodenal enteroids
  109. P51 | Evaluation of potential anti‐inflammatory and barrier‐enhancing effects of indoles on the canine duodenum using intestinal organoids
  110. O90 | Lung organoids as a novel model to study the pathogenesis of swine respiratory diseases
  111. O88 | Prediction of treatment response using canine urine‐derived bladder cancer organoids
  112. O63 | Population pharmacokinetics and absolute oral bioavailability of lasalocid ionophore in laying hens
  113. Concentrations of penicillin and gentamicin following intrauterine administration of two compounded formulations
  114. Leveraging Data from Spontaneous Animal Disease Models to Streamline Pharmaceutical Research: A Tale of Two Species
  115. Comprehensive characterization of the effect of mineralocorticoid receptor antagonism with spironolactone on the renin-angiotensin-aldosterone system in healthy dogs.
  116. Sa1767 SYNBIOTIC-IGY THERAPY MODULATES THE MUCOSAL MICROBIOME AND INFLAMMATORY INDICES IN DOGS WITH CHRONIC INFLAMMATORY ENTEROPATHY: A RANDOMIZED, CONTROLLED PILOT TRIAL
  117. Canine Intestinal Organoids as a Novel In Vitro Model of Intestinal Drug Permeability: A Proof-of-Concept Study
  118. Canine Intestinal Organoids as a Novel In Vitro Model of Intestinal Drug Permeability: A Proof-of-Concept Study
  119. Abstract 2509: Similar variant histology and immune cell infiltration in canine and human muscle-invasive bladder cancer
  120. Exploring the secrets of super-aging: a UK Biobank study on brain health and cognitive function
  121. Understanding the background and clinical significance of the WHO, WOAH, and EMA classifications of antimicrobials to mitigate antimicrobial resistance
  122. Pharmacokinetics of intramuscular maropitant in pigs (Sus scrofa domesticus)
  123. Breakthrough: a first-in-class virtual simulator for dose optimization of ACE inhibitors in translational cardiovascular medicine
  124. Characterization of the First Turtle Organoids: A Model for Investigating Unique Adaptations with Biomedical Potential
  125. Dose–response of benazepril on biomarkers of the classical and alternative pathways of the renin–angiotensin–aldosterone system in dogs
  126. Retrospective evaluation of the effect of inhalant anesthesia on complications and recurrence rates in feline urethral obstruction
  127. Pharmacokinetic and pharmacodynamic properties of pantoprazole in calves
  128. Ionophore coccidiostats – disposition kinetics in laying hens and residues transfer to eggs
  129. Joint Modeling of First-Line Therapeutics in Non-Small Cell Lung Cancer Using Large Database Reveals Potential Benefits of Scheduling Optimization
  130. Retrospective Comparison of Outcomes in Septic Peritonitis With or Without Closed-Suction Abdominal Drainage in 115 Dogs (2009-2019)
  131. Synbiotic-IgY Therapy Modulates the Mucosal Microbiome and Inflammatory Indices in Dogs with Chronic Inflammatory Enteropathy: A Randomized, Double-Blind, Placebo-Controlled Study
  132. Pilot safety evaluation of doxorubicin chemotherapy combined with non-specific immunotherapy (Immunocidin®) for canine splenic hemangiosarcoma
  133. Comparison of the pharmacokinetics of continuous and intermittent infusions of ampicillin-sulbactam in dogs with septic peritonitis
  134. Breakthrough: A First-In-Class Virtual Simulator for Dose Optimization of ACE Inhibitors in Translational Cardiovascular Medicine
  135. Breakthrough: A First-In-Class Virtual Simulator for Dose Optimization of ACE Inhibitors in Veterinary Cardiology
  136. Linear external skeletal fixation applied in minimally invasive fashion for stabilization of nonarticular tibial fractures in dogs and cats
  137. Culture and characterization of canine and feline corneal epithelial organoids: A new tool for the study and treatment of corneal diseases
  138. Retrospective evaluation of risk factors for development of kidney injury after parenteral furosemide treatment of left‐sided congestive heart failure in dogs
  139. Kinetics and minimal inhibitory concentrations of ceftiofur in tear film following extended-release parenteral administration (Excede®) in dogs
  140. Bioenergetic and vascular predictors of potential super-ager and cognitive decline trajectories—a UK Biobank Random Forest classification study
  141. Ketogenic diets in healthy dogs induce gut and serum metabolome changes suggestive of anti‐tumourigenic effects: A model for human ketotherapy trials
  142. Dose-response of benazepril on biomarkers of the classical and alternative pathways of the renin-angiotensin-aldosterone system in dogs
  143. Differential Transcriptomic Profiles Following Stimulation with Lipopolysaccharide in Intestinal Organoids from Dogs with Inflammatory Bowel Disease and Intestinal Mast Cell Tumor
  144. A Multi-Tissue Comparison and Molecular Characterization of Canine Organoids
  145. Letter regarding “Gastrointestinal foreign bodies in pet pigs: 17 cases”
  146. Evaluation of the Use of External Skeletal Fixation in Minimally Invasive Fashion for the Treatment of Non-articular Tibial Fractures
  147. Abstract 3092: Urine-derived urinary carcinoma organoids: A novel tool for providing new insights into human and canine bladder cancer treatment
  148. Retrospective Evaluation of Clinical Bleeding in Dogs With Anticoagulant Rodenticide Toxicity—A Multi-Center Evaluation of 62 Cases (2010–2020)
  149. Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneous Tumors
  150. Using machine learning to predict COVID-19 infection and severity risk among 4510 aged adults: a UK Biobank cohort study
  151. SGLT2 Inhibitors and Potential Applications in Treating Metabolic Syndrome
  152. Comparisons of plasma and fecal pharmacokinetics of danofloxacin and enrofloxacin in healthy and Mannheimia haemolytica infected calves
  153. Circulating renin‐angiotensin‐aldosterone system activity in cats with systemic hypertension or cardiomyopathy
  154. Canine Intestinal Organoids in a Dual-Chamber Permeable Support System
  155. Canine Intestinal Organoids in a Dual-Chamber Permeable Support System
  156. Computed Tomographic Evaluation of Mid-thoracic Vertebral Corridors in Normal French Bulldogs
  157. Standardization and Maintenance of 3D Canine Hepatic and Intestinal Organoid Cultures for Use in Biomedical Research
  158. Standardization and Maintenance of 3D Canine Hepatic and Intestinal Organoid Cultures for Use in Biomedical Research
  159. Differential Transcriptomic Profiles in Canine Intestinal Organoids Following Lipopolysaccharide Stimulation
  160. Suspected primary hyperreninism in a cat with malignant renal sarcoma and global renin‐angiotensin‐aldosterone system upregulation
  161. Multiomic analysis defines the first microRNA atlas across all small intestinal epithelial lineages and reveals novel markers of almost all major cell types
  162. Albumin in Tears Modulates Bacterial Susceptibility to Topical Antibiotics in Ophthalmology
  163. Harnessing the Biology of Canine Intestinal Organoids to Heighten Understanding of Inflammatory Bowel Disease Pathogenesis and Accelerate Drug Discovery: A One Health Approach
  164. Current diagnostics for chronic enteropathies in dogs
  165. Clinical efficacy of prebiotics and glycosaminoglycans versus placebo In dogs with food responsive enteropathy receiving a hydrolyzed diet: A pilot study
  166. 109 Diet-induced Clinical Responsiveness of Translational Dog Model for Human Western Diet (WD)-related Disease Research
  167. Pharmacokinetics of Pantoprazole and Pantoprazole Sulfone in Goats After Intravenous Administration: A Preliminary Report
  168. Pharmacokinetics of tulathromycin in pregnant ewes (Ovis aries) challenged with Campylobacter jejuni
  169. CULTURE AND MAINTENANCE OF URINE-DERIVED, 3-DIMENSIONAL CANINE TRANSITIONAL CELL CARCINOMA ORGANOIDS
  170. Retrospective evaluation of a dose‐dependent effect of angiotensin‐converting enzyme inhibitors on long‐term outcome in dogs with cardiac disease
  171. Computed tomography evaluation of proposed implant corridors in canine thoracic vertebrae
  172. Inflammation, negative affect, and amyloid burden in Alzheimer’s disease: Insights from the kynurenine pathway
  173. Focused ultrasound of the caudal vena cava in dogs with cavitary effusions or congestive heart failure: A prospective, observational study
  174. Corrigendum: Comparative Pharmacokinetics of Meloxicam Between Healthy Post-partum vs. Mid-lactation Dairy Cattle
  175. Gene Editing and Gene Therapy: Entering Uncharted Territory in Veterinary Oncology
  176. Radiation exposure associated with percutaneous fluoroscopically guided lag screw fixation for sacroiliac luxation in dogs
  177. Short‐term outcomes of 59 dogs treated for ilial body fractures with locking or non‐locking plates
  178. Su124 HOMOLOGY DIRECTED REPAIR IN CANINE DUODENAL ENTEROIDS TO MIMIC THE WILD-TYPE P-GLYCOPROTEIN MUTATION
  179. Comparison of Canine and Human Physiological Factors: Understanding Interspecies Differences that Impact Drug Pharmacokinetics
  180. Clinical Efficacy of Prebiotics and Glycosaminoglycans versus Placebo In Dogs with Food Responsive Enteropathy Receiving a Hydrolyzed Diet: A Pilot Study
  181. Effect of prazosin on feline recurrent urethral obstruction
  182. Presentation, Clinical Pathology Abnormalities, and Identification of Gastrointestinal Parasites in Camels (Camelus bactrianus and Camelus dromedarius) Presenting to Two North American Veterinary Teaching Hospitals. A Retrospective Study: 1980–2020
  183. Influence of Schirmer strip wetness on volume absorbed, volume recovered, and total protein content in canine tears
  184. A Multi-Institutional Retrospective Analysis of Toceranib Phosphate for Presumed or Confirmed Canine Aortic Body Chemodectomas
  185. Letter to the editor regarding “Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial”
  186. Emerging Roles of Urine-Derived Components for the Management of Bladder Cancer: One Man’s Trash Is Another Man’s Treasure
  187. Comprehensive Joint Modeling of First-Line Therapeutics in Non-Small Cell Lung Cancer
  188. Pharmacokinetics and Tissue Levels of Pantoprazole in Neonatal Calves After Intravenous Administration
  189. Genetic Factors of Alzheimer’s Disease Modulate How Diet is Associated with Long-Term Cognitive Trajectories: A UK Biobank Study
  190. Emerging Roles of Urine-Derived Components for the Management of Bladder Cancer: One Man’s Trash is Another Man’s Treasure
  191. Genetics and Immunopathogenesis of Chronic Inflammatory Enteropathies in Dogs
  192. Impact of diurnal variation, sex, tear collection method, and disease state on tear protein levels in dogs
  193. Tear Film Pharmacokinetics and Systemic Absorption Following Topical Administration of 1% Prednisolone Acetate Ophthalmic Suspension in Dogs
  194. Pharmacokinetics of Oral Prednisone at Various Doses in Dogs: Preliminary Findings Using a Naïve Pooled-Data Approach
  195. Considerations in the extrapolation of drug toxicity between humans and dogs
  196. Evaluation of a Pasteurella multocida Respiratory Disease Induction Model for Goats (Capra aegagrus hircus)
  197. Non-Linear Mixed-Effects Pharmacokinetic Modeling of the Novel COX-2 Selective Inhibitor Vitacoxib in Cats
  198. Determination of the milk pharmacokinetics and depletion of milk residues following intramammary administration of cephapirin sodium in lactating dairy goats
  199. Serum albumin and total protein concentration in the tear film of horses with healthy or diseased eyes
  200. Comparative Pharmacokinetics of Meloxicam Between Healthy Post-partum vs. Mid-lactation Dairy Cattle
  201. Pharmacokinetics of Intravenous, Intramuscular, Oral, and Transdermal Administration of Flunixin Meglumine in Pre-wean Piglets
  202. Neuroinflammation, Depressive Affect, and Amyloid Burden in Alzheimer’s Disease: Insights from the Kynurenine Pathway
  203. Effects of the estrous cycle and pregnancy status on cardiovascular variables in healthy bitches
  204. An eye on the dog as the scientist's best friend for translational research in ophthalmology: Focus on the ocular surface
  205. Treatment With Hydrolyzed Diet Supplemented With Prebiotics and Glycosaminoglycans Alters Lipid Metabolism in Canine Inflammatory Bowel Disease
  206. Impact of acute conjunctivitis on ocular surface homeostasis in dogs
  207. Walking in the Light: How History of Physical Activity, Sunlight, and Vitamin D Account for Body Fat—A UK Biobank Study
  208. An Eye on the Dog as the Scientist’s Best Friend for Translational Research in Ophthalmology: Focus on the Ocular Surface
  209. Sa1976 POLYPHENOLS REVERSE THE PATHOLOGIC EFFECTS OF PALMITIC ACID AND HIGH FAT DIET IN CANINE ENTEROIDS
  210. Recapitulation of the accessible interface of biopsy-derived canine intestinal organoids to study epithelial-luminal interactions
  211. Evaluation of dose-response effects of short-term oral prednisone administration on clinicopathologic and hemodynamic variables in healthy dogs
  212. Harnessing The Biology of Intestinal Organoids To Accelerate Drug Discovery in Inflammatory Bowel Disease: A One Health Approach
  213. Serum Vitamin B12, and Related MTRR and Cubilin Genotypes, Predict Neural Outcomes across the AD Spectrum
  214. A Retrospective Clinical Investigation of the Safety and Adverse Effects of Pantoprazole in Hospitalized Ruminants
  215. Investigation of Schirmer tear test-1 for measurement of tear production in cats in various environmental settings and with different test durations
  216. Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors
  217. Apparent total tract digestibility, fecal characteristics, and blood parameters of healthy adult dogs fed high-fat diets
  218. Albumin Levels in Tear Film Modulate the Bioavailability of Medically-Relevant Topical Drugs
  219. CSF glucose tracks regional tau progression based on Alzheimer's disease risk factors
  220. Glucocorticoid and dietary effects on mucosal microbiota in canine inflammatory bowel disease
  221. Kinetics of Fluorescein in Tear Film After Eye Drop Instillation in Beagle Dogs: Does Size Really Matter?
  222. Nerve growth factor in dogs: Assessment of two immunoassays and selected ocular parameters following a nicergoline challenge per os
  223. In vitro Cytotoxicity and Pharmacokinetic Evaluation of Pharmacological Ascorbate in Dogs
  224. Aging-related changes in fluid intelligence, muscle and adipose mass, and sex-specific immunologic mediation: A longitudinal UK Biobank study
  225. Re: “Evaluation of Enrofloxacin for Use in Cryopreservation of Zebu Bull (Bos indicus) Semen” by Ishaq et al. (Biopreserv Biobank 2019;[Epub ahead of print]; DOI: 10.1089/bio.2018.0133)
  226. Pharmacokinetic Modeling of Ceftiofur Sodium Using Non-linear Mixed-Effects in Healthy Beagle Dogs
  227. Comparative pharmacokinetics of meloxicam between healthy postpartum versus mid-lactation dairy cows
  228. Fluorophotometric Assessment of Tear Volume and Turnover Rate in Healthy Dogs and Cats
  229. Clinicopathologic, hemodynamic, and echocardiographic effects of short-term oral administration of anti-inflammatory doses of prednisolone to systemically normal cats
  230. Nonlinear mixed‐effects pharmacokinetic modeling of the novel COX‐2 selective inhibitor vitacoxib in dogs
  231. Pharmacokinetic Modeling of Ceftiofur Sodium Using Nonlinear Mixed-Effects in Healthy Beagle Dogs
  232. Histamine-Induced Conjunctivitis and Breakdown of Blood–Tear Barrier in Dogs: A Model for Ocular Pharmacology and Therapeutics
  233. Microbiota-Related Changes in Unconjugated Fecal Bile Acids Are Associated With Naturally Occurring, Insulin-Dependent Diabetes Mellitus in Dogs
  234. The Gut-Brain Axis in Neurodegenerative Diseases and Relevance of the Canine Model: A Review
  235. A reduced Gompertz model for predicting tumor age using a population approach
  236. Effects of experimentally induced respiratory disease on the pharmacokinetics and tissue residues of tulathromycin in meat goats
  237. Indoleamine-pyrrole 2,3-dioxygenase-1 (IDO-1) mRNA is over-expressed in the duodenal mucosa and is negatively correlated with serum tryptophan concentrations in dogs with protein-losing enteropathy
  238. Interleukin‐13 and interleukin‐33 mRNA are underexpressed in the duodenal mucosa of German Shepherd dogs with chronic enteropathy
  239. Paper spray high-resolution accurate mass spectrometry for quantitation of voriconazole in equine tears
  240. Tear Fluid Pharmacokinetics Following Oral Prednisone Administration in Dogs With and Without Conjunctivitis
  241. Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
  242. 449 – High Fat Ketogenic Diet Decreases Serum Lipid Metabolites in Healthy Dogs
  243. Sa1098 – Molecular Response of Canine Intestinal Organoids to Gastrointestinal Nematode Extracellular Vesicles
  244. Su1812 – Treatment with Hydrolyzed Diet Supplemented with Prebiotics and Glycosaminoglycans Improves Abnormalities in Lipid Metabolism in a Canine Model of Inflammatory Bowel Disease
  245. Su2043 – A Novel Canine Intestinal Organoid Model to Characterize Dose-Exposure-Response of Chemotherapeutic Drugs
  246. Derivation of adult canine intestinal organoids for translational research in gastroenterology
  247. CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies
  248. A Review of Relevant Therapeutic Targets for the Management of Congestive Heart Failure in Dogs: Present and Future Directions
  249. Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer
  250. Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation
  251. The Role of the Gut-Brain Axis in Neurodegenerative Diseases and Relevance of the Canine Model: A Review
  252. Pharmacokinetics of Ertapenem in Sheep (Ovis aries) with Experimentally Induced Urinary Tract Infection
  253. Workshop Report: USP Workshop on Exploring the Science of Drug Absorption
  254. Population Modeling of Tumor Growth Curves, the Reduced Gompertz Model and Prediction of the Age of a Tumor
  255. Correlating Gastrointestinal Histopathologic Changes to Clinical Disease Activity in Dogs With Idiopathic Inflammatory Bowel Disease
  256. CAR T-Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds against Hematological Malignancies
  257. Relative Oral Bioavailability of Two Amoxicillin–Clavulanic Acid Formulations in Healthy Dogs: A Pilot Study
  258. Clinical features of cats with aqueous tear deficiency: a retrospective case series of 10 patients (17 eyes)
  259. Adult Canine Intestinal Derived Organoids: A Novel In Vitro System for Translational Research in Comparative Gastroenterology
  260. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs
  261. Sacubitril/valsartan (LCZ696) Significantly Reduces Aldosterone and Increases cGMP Circulating Levels in a Canine Model of RAAS Activation
  262. Comparative plasma and interstitial fluid pharmacokinetics and tissue residues of ceftiofur crystalline-free acid in cattle with induced coliform mastitis
  263. Adverse reactions to fentanyl transdermal patches in calves: a preliminary clinical and pharmacokinetic study
  264. Impact of Flow Rate, Collection Devices, and Extraction Methods on Tear Concentrations Following Oral Administration of Doxycycline in Dogs and Cats
  265. Population variability in animal health: Influence on dose-exposure-response relationships: Part II: Modelling and simulation
  266. Mo1059 - Comparison of Endoscopically (Egd/Colo) Procured Enteroids and Colonoids from Normal Dogs and Dogs with Naturally Occurring Chronic Enteropathies (IBD)
  267. Effects of short-term anti-inflammatory glucocorticoid treatment on clinicopathologic, echocardiographic, and hemodynamic variables in systemically healthy dogs
  268. Pharmacokinetics of fentanyl citrate and norfentanyl in Holstein calves and effect of analytical performances on fentanyl parameter estimation
  269. Effect of tear collection on lacrimal total protein content in dogs and cats: a comparison between Schirmer strips and ophthalmic sponges
  270. Comparison of milk and plasma pharmacokinetics of meloxicam in postpartum versus mid-lactation Holstein cows
  271. Network on veterinary medicines initiated by the European Federation For Pharmaceutical Sciences
  272. Intestinal Stem Cells to Advance Drug Development, Precision, and Regenerative Medicine: A Paradigm Shift in Translational Research
  273. Mathematical modeling and simulation in animal health. Part III: Using nonlinear mixed-effects to characterize and quantify variability in drug pharmacokinetics
  274. Model-Based Reverse Translation Between Veterinary and Human Medicine: The One Health Initiative
  275. Pharmacokinetics and adverse reactions to fentanyl transdermal patches in healthy and hospitalized calves
  276. Tear fluid collection in dogs and cats using ophthalmic sponges
  277. Modeling of Large Pharmacokinetic Data Using Nonlinear Mixed-Effects: A Paradigm Shift in Veterinary Pharmacology. A Case Study With Robenacoxib in Cats
  278. Position Paper: EUFEPS Network on Veterinary Medicines Initiative
  279. Multiple comparison procedure and modeling: a versatile tool for evaluating dose-response relationships in veterinary pharmacology - a case study with furosemide
  280. Mathematical modeling and simulation in animal health - Part II: principles, methods, applications, and value of physiologically based pharmacokinetic modeling in veterinary medicine and food safety assessment
  281. Mathematical modeling and simulation in animal health. Part I: Moving beyond pharmacokinetics
  282. Chronobiology and Pharmacologic Modulation of the Renin–Angiotensin–Aldosterone System in Dogs: What Have We Learned?
  283. Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs
  284. FIRST-IN-CLASS ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR LCZ696 MODULATES THE DYNAMICS OF THE RENIN CASCADE AND NATRIURETIC PEPTIDES SYSTEM WITH SIGNIFICANT REDUCTION OF ALDOSTERONE EXPOSURE
  285. Influence of feeding schedules on the chronobiology of renin activity, urinary electrolytes and blood pressure in dogs
  286. Population pharmacokinetic analysis of blood concentrations of robenacoxib in dogs with osteoarthritis
  287. Chronobiology of the renin-angiotensin-aldosterone system in dogs: relation to blood pressure and renal physiology
  288. Animal Health Modeling & Simulation Society: a new society promoting model-based approaches in veterinary pharmacology
  289. Response to letter from Atkinset al. Capturing the dynamics of systemic Renin‐Angiotensin‐Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs
  290. Capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs
  291. Pharmacokinetics of extravascular maropitant citrate in swine